Natural Phenomenon or Process
Black Diamond Therapeutics Refocuses on Lung Cancer Drug BDTX-1535 Amid Workforce Reduction
Black Diamond Therapeutics, workforce reduction, lung cancer drug, BDTX-1535, EGFR mutations, Tagrisso, tyrosine kinase inhibitor
Baxter’s IV Fluid Production Halted Indefinitely Due to Hurricane Helene Damage
Hurricane Helene, IV fluid shortage, Baxter International, North Carolina factory, healthcare supply chain, hospital preparedness
Relay Therapeutics Announces Additional Layoffs to Achieve $50M Annual Savings
Relay Therapeutics, layoffs, cost-cutting, biotech industry, workforce reduction
Relay Therapeutics Announces 10% Workforce Reduction to Streamline Research Organization
Relay Therapeutics, layoffs, workforce reduction, biotech, research organization, streamlining
Pharmaceutical Giants J&J, Bayer, and Pfizer Announce Layoffs Affecting Nearly 500 Employees
Layoffs, Pharmaceutical Industry, Johnson & Johnson, Bayer, Pfizer, Biotech Layoffs, Workforce Reduction
IGM Biosciences Undergoes Strategic Pivot to Autoimmune Diseases, Overhauls Leadership and Reduces Workforce
IGM Biosciences, autoimmune diseases, strategic pivot, T cell-engaging IgM antibodies, leadership changes, workforce reduction, imvotamab, IGM-2644
Shattuck Labs Shifts Focus to IBD Drug, Discontinues CD47 Program and Reduces Workforce by 40%
Shattuck Labs, CD47 program, workforce reduction, IBD drug, SL-325, DR3 antagonist antibody
Enanta Pharmaceuticals Achieves Breakthrough in RSV Treatment with EDP-323, Demonstrating Significant Reductions in Viral Load and Symptoms
Enanta Pharmaceuticals, EDP-323, Respiratory Syncytial Virus (RSV), Antiviral Treatment, Phase 2a Human Challenge Study, Viral Load Reduction, Symptom Alleviation
Bristol Myers Squibb Continues Layoffs, Cutting 79 More Jobs in New Jersey Amid $1.5B Cost Reduction Effort
Bristol Myers Squibb, layoffs, New Jersey, cost reduction, pharmaceutical industry
Aligos Therapeutics Reports Positive Phase IIa Results for MASH Treatment, Despite Investor Skepticism
Aligos Therapeutics, MASH (Metabolic Dysfunction-Associated Steatohepatitis), Phase IIa trial, ALG-055009, Liver fat reduction, Investor skepticism, Placebo effect